RXRX

3.42

3.95% 0.13

Dopo l'orario di chiusura: 3.40 -0.02 -0.58%

Recursion Pharmaceuticals Inc (RXRX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché RXRX Giù? Forum Previsione

Precedente Chiudi:

$3.29

Aprire:

$3.35

Volume 24 ore:

14.35M

Relative Volume:

0.68

Capitalizzazione di mercato:

$1.81B

Reddito:

$74.68M

Utile/perdita netta:

$-644.76M

Rapporto P/E:

-2.3063

EPS:

-1.4829

Flusso di cassa netto:

$-380.44M

1 W Prestazione:

-1.16%

1M Prestazione:

-2.01%

6M Prestazione:

-29.19%

1 anno Prestazione:

-42.42%

Intervallo 1D:

$3.345

$3.52

Intervallo di 1 settimana:

$3.22

$3.57

Portata 52W:

$2.98

$7.18

Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile

Nome

Recursion Pharmaceuticals Inc

Settore

Healthcare (1116)

Industria

Biotechnology (621)

Telefono

(385) 269-0203

Indirizzo

41S RIO GRANDE STREET, SALT LAKE CITY

Dipendente

600

Cinguettio

Prossima data di guadagno

2024-11-06

Ultimi documenti SEC

RXRX's Discussions on Twitter

Compare RXRX vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
RXRX Recursion Pharmaceuticals Inc	3.42	1.81B	74.68M	-644.76M	-380.44M	-1.4829
VRTX Vertex Pharmaceuticals Inc	469.34	119.23B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	745.77	78.84B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	700.45	43.35B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	313.41	41.57B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.05	31.51B	5.36B	287.73M	924.18M	2.5229

Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-12-17	Aggiornamento	JP Morgan	Neutral → Overweight
2025-07-03	Ripresa	Morgan Stanley	Equal-Weight
2023-05-22	Iniziato	Morgan Stanley	Equal-Weight
2023-03-16	Iniziato	Needham	Buy
2022-09-16	Iniziato	KeyBanc Capital Markets	Overweight
2022-04-18	Downgrade	BofA Securities	Buy → Neutral
2022-03-04	Downgrade	SVB Leerink	Outperform → Mkt Perform
2021-09-21	Iniziato	Berenberg	Buy
2021-05-11	Iniziato	BofA Securities	Buy
2021-05-11	Iniziato	Goldman	Neutral
2021-05-11	Iniziato	JP Morgan	Neutral
2021-05-11	Iniziato	KeyBanc Capital Markets	Overweight
2021-05-11	Iniziato	SVB Leerink	Outperform

Mostra tutto

Recursion Pharmaceuticals Inc Borsa (RXRX) Ultime notizie

Mar 13, 2026

What makes Recursion Pharmaceuticals (RXRX) so attractive - MSN

Mar 13, 2026

Measuring the AI Bubble - Pharmaceutical Executive

Mar 13, 2026

Jim Cramer on Recursion Pharmaceuticals: “It’s a Let Down, Big Let Down” - Insider Monkey

Mar 13, 2026

A Look At Recursion Pharmaceuticals (RXRX) Valuation After Q4 Beat And AI Clinical Progress - Sahm

Mar 13, 2026

Mar 12, 2026

PARG inhibitors disclosed in Recursion Pharmaceuticals patent - bioworld.com

Mar 12, 2026

Mar 11, 2026

Recursion Pharmaceuticals and Applied Digital shares fall after Nvidia exits stakes - MSN

Mar 11, 2026

Recursion Pharmaceuticals (NASDAQ:RXRX) CEO Sells $94,798.30 in Stock - MarketBeat

Mar 11, 2026

Recursion (NASDAQ: RXRX) director converts 20K Class B, gifts 20K A - Stock Titan

Mar 11, 2026

Mar 10, 2026

Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance

Mar 10, 2026

Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Recent 1‑Year Share Slump Accurately - Yahoo Finance

Mar 10, 2026

A Look At Recursion Pharmaceuticals (RXRX) Valuation After AI Milestone And Improved Quarterly Results - Yahoo Finance

Mar 10, 2026

Mar 09, 2026

Recursion’s First AI Clinical Proof Links Pipeline Progress With Valuation Gap - Yahoo Finance

Mar 09, 2026

Day Trade: Why retail investors pile into Recursion Pharmaceuticals Inc. stockTrade Analysis Summary & Community Supported Trade Ideas - Naître et grandir

Mar 07, 2026

symbol__ Stock Quote Price and Forecast - CNN

Mar 07, 2026

10 Low Risk Penny Stocks to Buy Now - Insider Monkey

Mar 07, 2026

Mar 06, 2026

Recursion Pharmaceuticals’ Earnings Call Highlights AI Momentum - TipRanks

Mar 06, 2026

Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia - MSN

Mar 06, 2026

BoFA Lowers PT on Recursion Pharmaceuticals (RXRX), Keeps a Hold Rating - Insider Monkey

Mar 06, 2026

Assessing Recursion Pharmaceuticals (RXRX) Valuation After Earnings Jump And New Equity Offering Plans - Sahm

Mar 06, 2026

Recursion Pharmaceuticals (RXRX) Is Down 6.1% After Insider Sale And New ATM Equity ProgramHas The Bull Case Changed? - Sahm

Mar 06, 2026

Mar 05, 2026

ARK Investment Management LLC Purchases 556,868 Shares of Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat

Mar 05, 2026